NCT02660424已完成2 期
A Phase 2a Randomized, Double-blind, Placebo-Controlled, Crossover Study of the Efficacy and Safety of VX-150 in Subjects With Osteoarthritis of the Knee
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 124
- 主要终点
- Change from baseline in Western Ontario and McMaster Universities (WOMAC) osteoarthritis index pain subscale score at Day 14
研究概览
简要总结
The Primary objective of this study is to evaluate the efficacy of VX-150 in the treatment of osteoarthritis pain
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 40 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Willing and able to comply with scheduled visits, treatment plan, study restrictions, laboratory tests, contraceptive guidelines, and other study procedures.
- •Subjects (male and female [of non-childbearing potential]) will be between the ages of 40 and 80 years, inclusive. Female subjects must have a negative pregnancy test at Screening and on Day 1 of each Treatment Period and must not be nursing; male subjects must not have a female partner who is pregnant or nursing.
- •Body mass index (BMI) of 18.0 to 38.0 kg/m2, inclusive, and a total body weight of 50 to 150 kg.
- •Ambulatory with osteoarthritis of the knee with symptoms for at least 6 months and pain on the majority of days for the past 30 days. Symptoms must include knee joint pain. In subjects with bilateral knee osteoarthritis, the more symptomatic knee will be considered the index knee.
- •Radiographic evidence of at least one tibiofemoral osteophyte in the index knee within 12 months before the Day 1 Visit.
- •WOMAC pain subscale score
排除标准
- •History in the past 10 years of reactive arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, arthritis associated with inflammatory bowel disease, sarcoidosis, amyloidosis or fibromyalgia.
- •History in the past 10 years of malignancy with the exception of resected basal cell carcinoma, squamous cell carcinoma of the skin or resected cervical atypia or carcinoma in situ.
- •History of cardiac dysrhythmias requiring anti-arrythmia treatment(s).
- •History of abnormal laboratory results ≥2.5 × upper limit of normal (ULN) indicative of any significant medical disease which in the opinion of the investigator would preclude the subjects participation in the study.
- •A known or clinically suspected infection with human immunodeficiency virus or hepatitis B or C viruses.
- •Other serious, acute or chronic medical or psychiatric illness that in the judgment of the investigator could compromise subject safety, limit the subject's ability to complete the study and/or compromise the objectives of the study.
- •Either participated within 3 months in another investigational study in which the subject was exposed to study drugs or vaccines,or will participate concurrently in such study.
- •History of drug or alcohol dependence in the past 3 years, or a positive test for drugs of abuse at the Screening Visit.
- •Requires opioids for pain relief.
- •Changed analgesic treatment regimen within 30 days of the Screening Visit.
- •Received or plan to receive short acting hyaluronic acid, corticosteroid, or other intra-articular injections as follows:
- •in the index knee within 3 months of the Screening Visit, or at any time during the study
- •in any other joint within 4 weeks of the Screening Visit, or at any time during the study
- •Received or plan to receive long acting hyaluronic acid or other intra-articular injections as follows:
- •in the index knee within 6 months of the Screening Visit, or at any time during the study
- •in any other joint within 4 weeks of the Screening Visit, or at any time during the study
- •History of arthroscopic or open surgery within 12 months before the Screening Visit, or have a planned surgery during, or immediately after, study follow-up.
- •History of joint replacement surgery in the index knee.
- •Significant hip pain, ipsilateral to the index knee that may interfere with assessments of index knee pain.
- •Clinical signs and symptoms of an active knee infection.
- •Current use of a handicap assistance device (unilateral assistance device such as a cane is permitted).
- •Started a new physical therapy, weight loss, or exercise program within 3 months of the Screening Visit, or are not willing to maintain a stable program during the course of the study.
- •Lab abnormalities at the screening visit.
研究组 & 干预措施
VX-150, placebo
Experimental
Sequence 1: VX-150 in Treatment Period 1→washout→ placebo in Treatment Period 2
干预措施: VX-150 (Drug)
VX-150, placebo
Experimental
Sequence 1: VX-150 in Treatment Period 1→washout→ placebo in Treatment Period 2
干预措施: Placebo (Drug)
placebo, VX-150
Experimental
Sequence 2: placebo in Treatment Period 1→washout→ VX-150 in Treatment Period 2
干预措施: VX-150 (Drug)
placebo, VX-150
Experimental
Sequence 2: placebo in Treatment Period 1→washout→ VX-150 in Treatment Period 2
干预措施: Placebo (Drug)
结局指标
主要结局
Change from baseline in Western Ontario and McMaster Universities (WOMAC) osteoarthritis index pain subscale score at Day 14
时间窗: from baseline at Day 14
次要结局
- Plasma PK parameters of prodrug, VX-150 and its primary metabolite: AUC [area under the plasma concentration-time curve](Days 1,14,16,18 of each treatment periods)
- Plasma PK parameters of prodrug, VX-150 and its primary metabolite: Tmax [time to maximum plasma concentration](Days 1,14 of each treatment periods)
- Proportion of subjects with ≥50% reduction in WOMAC pain subscale at Day 14(at Day 14)
- Use of rescue medications [to be obtained by electronic diary and questionnaire](Treatment periods1 (14 days) and 2 (14 days))
- Change from baseline in total WOMAC score at Day 14(at Day 14)
- Safety and tolerability based on the incidence and type of adverse events (AEs),changes from baseline in clinically significant laboratory test results, and assessment of 12 lead electrocardiograms (ECGs) and vital signs at designated visits.(up to 12 weeks (duration of study))
- Plasma PK parameters of prodrug, VX-150 and its primary metabolite: Cmax [maximum plasma concentrations](Days 1,14 of each treatment periods)
研究者
相似试验
已完成
2 期
A Dose-ranging Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following BunionectomyAcute PainNCT03764072Vertex Pharmaceuticals Incorporated250
已完成
1 期
Preliminary Evaluation of Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Osteoarthritic PainOsteoarthritis, KneeNCT03282149Xalud Therapeutics, Inc.24
已完成
2 期
Evaluation of Efficacy and Safety of VX-548 for Painful Lumbosacral Radiculopathy (PLSR)Painful Lumbosacral RadiculopathyNCT06176196Vertex Pharmaceuticals Incorporated218
已完成
2 期
A Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702Rheumatoid ArthritisNCT00395577Vertex Pharmaceuticals Incorporated120
已完成
2 期
Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental GlomerulosclerosisGlomerulosclerosis, Focal SegmentalNCT04340362Vertex Pharmaceuticals Incorporated16